Zenas Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zenas Biopharma, Inc. (Nasdaq: ZBIO) on February 13, 2026, reporting events occurring on February 10, 2026. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Waltham, MA.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and compensation plans rather than financial performance results.
Material Changes
On February 10, 2026, the Board of Directors approved the Amended and Restated Short-Term Incentive Plan (STI Plan), effective as of January 1, 2026. This plan replaces or updates the previous framework for annual discretionary cash bonuses for full- and part-time employees.
Guidance, Outlook, and Management Commentary
- Plan Administration: The Board administers the plan for executives, while the CEO and leadership team administer it for other eligible employees.
- Payment Terms: Bonuses are based on Company performance and individual goals. Payments are made no later than March 15 following the end of the calendar year.
- Eligibility: Participants must remain employed through the payment date to receive awards.
- Clawback Provisions: Awards are subject to the Company's Policy for Recoupment of Incentive Compensation.
- Discretion: The Company reserves the right to amend or discontinue the plan at any time without prior notice.
Key Facts for Investor Verification
- Review the full text of the Amended and Restated Short-Term Incentive Plan filed as Exhibit 10.1 to understand specific performance metrics and payout caps.
- Verify the Company's current cash position to assess its ability to fund discretionary cash bonuses under the new plan.
- Monitor future filings for any amendments to the plan or changes in executive compensation structures.